Short interest for Amedisys gives investors a sense of the degree to which investors are betting on the decline of Amedisys's stock. Short interest data is updated every two weeks.

Amedisys Stock (NASDAQ:AMED), Short Interest Report

Amedisys

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

News

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMED

ARCB

NFLX

PTGX

REGN


	Morgan Stanley cut the price target for  ArcBest Corporation  (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.


Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday

Analyst Color

Biotech

Health Care

General

OPCH

Optum&#39;s Decision To Target Amedisys Is Intriguing, Says Analyst

Movers

Amedisys Inc (NASDAQ: AMED) shares are up Monday after the company announced that it received an unsolicited proposal from Optum, a diversified health services company, to acquire all of the outstanding shares of Amedisys&#39; common stock.

Why Shares Of Amedisys Inc Are Rising

Amedisys Inc

AMEDEO AIR FOUR PLUS LTD by AMEDEO AIR FOUR PLUS LTD

<p>Cantor Fitzgerald  analyst Sarah James   reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.</p>


Reiteration

Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target

<p>Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.98 percent.  The company reported quarterly sales of $571.400 million which beat the analyst consensus estimate of $565.380 million by 1.06 percent.  This is a 2.70 percent increase over sales of $556.389 million the same period last year.</p>


Earnings

Earnings Beats

Amedisys Q1 2024 Adj EPS $1.03 Beats $1.02 Estimate, Sales $571.400M Beat $565.380M Estimate

<p>Raymond James  analyst John Ransom   maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Market Perform to Market Perform.</p>


Raymond James Maintains Market Perform on Amedisysto Market Perform

<p>RBC Capital  analyst Ben Hendrix   maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Outperform and raises the price target from $97 to $100.</p>


RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100

<p>Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by 8.74 percent.  The company reported quarterly sales of $570.800 million which beat the analyst consensus estimate of $567.713 million by 0.54 percent.  This is a 1.55 percent increase over sales of $562.064 million the same period last year.</p>


Earnings Misses

Amedisys Q4 2023 Adj EPS $0.940 Misses $1.030 Estimate, Sales $570.800M Beat $567.713M Estimate

<p>Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8.74 percent.  The company reported quarterly sales of $570.80 million which beat the analyst consensus estimate of $567.71 million by 0.54 percent.  This is a 1.55 percent increase over sales of $562.06 million the same period last year.</p>


Amedisys Q4 2023 Adj EPS $0.94 Misses $1.03 Estimate, Sales $570.80M Beat $567.71M Estimate

<p>Amedisys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes.<br /><br />&nbsp;</p>
<p>Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions. With improved accuracy, sensitivity and specificity, molecular testing significantly enhances the ability to identify infectious pathogens, supporting timely and targeted care strategies.</p>
<p>"We are excited to integrate molecular testing capabilities into our infection diagnosis protocols," states Cyndi Shook, Senior Vice President of Clinical Operations at Amedisys. "This advancement represents a significant step in our ongoing commitment to providing the highest quality of care to our patients. By leveraging the latest in diagnostic technology, we can further enhance the accuracy and speed of infection testing, allowing us to tailor treatment plans to the individual needs of each patient."</p>
<p>"Patients Choice Laboratories is excited to partner with Amedisys, one of the leaders in the home health industry, in an effort to improve outcomes for patients suffering from infectious diseases," said Brad Moss, President at Patients Choice Laboratories. "Our automated pre-analytical, analytical and post-analytical processes in molecular technologies provide the necessary clinical decision support so that treatments are targeted and successful."</p>
<p>"According to the CDC, more than one-third of deaths of people over the age of 65 are caused by infectious diseases, thus making turnaround time critical so that the most appropriate treatment(s) are deployed in the early stages of infection," added Thomas Payne, Chief Operations Officer at Patients Choice Laboratories. "Molecular testing provides the speed and accuracy needed to detect pathogens across our entire infectious disease platform."</p>
<p>"Our partnership with Patient Choice Laboratories aligns seamlessly with our dedication to delivering exceptional care and optimizing patient outcomes," added Barbara Andazola, Vice President of Clinical Practice, Strategy and Programs at Amedisys. "By incorporating molecular testing into our infection diagnosis protocols, we are empowering our care teams to provide more accurate and effective treatments, ultimately reducing the impact of infections and preventing related hospitalizations."</p>
<p>Amedisys has implemented comprehensive protocols and training to ensure seamless integration of molecular testing into its care centers. The rollout of this innovative approach to infection diagnosis underscores the organization's commitment to staying at the forefront of healthcare advancements and technology, ultimately providing its patients with the highest standard of care and support.</p>
<p>For more information about Amedisys Home Health and its advanced molecular testing capabilities, please visit <a href="http://www.amedisys.com/">www.amedisys.com</a>.</p>


Amedisys Offers Molecular Testing For Rapid And Accurate Infection Diagnosis In Collaboration With Patient Choice Laboratories

<p><strong>Richard Ashworth</strong>, President and CEO at <strong>Amedisys</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), reported a large exercise of company stock options on December 28, according to a new SEC filing.</p>
<p><strong>What Happened:</strong> Ashworth, President and CEO at Amedisys, made a strategic move by exercising stock options for 11,237 shares of AMED as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000896262/000089626223000081//Archives/edgar/data/896262/000089626223000081/0000896262-23-000081-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $171,027.</p>
<p><strong>Amedisys</strong> shares are trading down 0.0% at $95.04 at the time of this writing on Friday morning. Since the current price is $95.04, this makes Ashworth's 11,237 shares worth $171,027.</p>
<h3>Get to Know Amedisys Better</h3>
<p>Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.</p>
<h3>Amedisys's Financial Performance</h3>
<p><strong>Revenue Growth:</strong> Amedisys's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately <strong>-0.31%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Exploring Profitability:</strong></p>
<ul>
<li>
<p><strong>Gross Margin:</strong> The company maintains a high gross margin of <strong>43.98%</strong>, indicating strong cost management and profitability compared to its peers.</p>
</li>
<li>
<p><strong>Earnings per Share (EPS):</strong> Amedisys's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of <strong>0.8</strong>.</p>
</li>
</ul>
<p><strong>Debt Management:</strong> Amedisys's debt-to-equity ratio is below the industry average. With a ratio of <b>0.47</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><strong>In-Depth Valuation Examination:</strong></p>
<ul>
<li>
<p><strong>Price to Earnings (P/E) Ratio:</strong> A higher-than-average P/E ratio of <strong>1188.0</strong> suggests caution, as the stock may be overvalued in the eyes of investors.</p>
</li>
<li>
<p><strong>Price to Sales (P/S) Ratio:</strong> With a lower-than-average P/S ratio of <strong>1.39</strong>, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.</p>
</li>
<li>
<p><strong>EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization):</strong> Amedisys's EV/EBITDA ratio of <strong>25.02</strong> exceeds industry averages, indicating a premium valuation in the market</p>
</li>
</ul>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><a href="https://www.schwab.com/brokerage?aff=XEC"><em>Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</em></a></p>
<h3>The Importance of Insider Transactions</h3>
<p>Insider transactions, although significant, should be considered within the larger context of market analysis and trends.</p>
<p>Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.</p>
<p>The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.</p>
<p>However, insider sells may not always signal a bearish view and can be influenced by various factors.</p>
<h3>The Insider's Guide to Important Transaction Codes</h3>
<p>For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A <strong>P</strong> in Box 3 denotes a purchase, while <strong>S</strong> signifies a sale. Transaction code <strong>C</strong> signals the conversion of an option, and transaction code <strong>A</strong> denotes a grant, award, or other acquisition of securities from the company.</p>
<p><a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896262"><strong>Check Out The Full List Of Amedisys's Insider Trades.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insider Trades

Richard Ashworth Exercises Options, Realizes $171K

<p>Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9.26 percent. This is a 14.78 percent decrease over earnings of $1.15 per share from the same period last year.  The company reported quarterly sales of $556.20 million which missed the analyst consensus estimate of $561.27 million by 0.90 percent.  This is a 0.32 percent decrease over sales of $557.99 million the same period last year.</p>


Amedisys Q3 Adj. EPS $0.98 Misses $1.08 Estimate, Sales $556.20M Miss $561.27M Estimate

<p>Cantor Fitzgerald has decided to maintain its Neutral rating of Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) and raise its price target from $100.00 to $101.00.</p>
<p>Shares of Amedisys are trading up 0.11% over the last 24 hours, at $93.61 per share.</p>
<p>A move to $101.00 would account for a 7.89% increase from the current share price.</p>
<h3>About Amedisys</h3>
<p>Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.</p>
<h3>About Analyst Ratings</h3>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Cantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To Know

<p>Cantor Fitzgerald  analyst Sarah James   maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and raises the price target from $100 to $101.</p>


Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101

<p>TD Cowen  analyst Gary Taylor   maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Market Perform and raises the price target from $84 to $101.</p>


TD Cowen Maintains Market Perform on Amedisys, Raises Price Target to $101

<p>Over the past 3 months, 11 analysts have published their opinion on Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>According to 11 analyst offering 12-month price targets in the last 3 months, Amedisys has an average price target of $98.82 with a high of $115.00 and a low of $84.00. </p>
<p>Below is a summary of how these 11 analysts rated Amedisys over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock</p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1690466417_0.png" alt="price target chart" /></p>
<p>This current average has decreased by 1.74% from the previous average price target of $100.57. </p>
<p><a href="https://www.benzinga.com/quote/AMED/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Amedisys analyst ratings.</strong></a></p>
<h1>How Are Analyst Ratings Determined?</h1>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 11 Analyst Ratings Have To Say About Amedisys

<p>Credit Suisse  analyst Jonathan Yong   reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.</p>


Credit Suisse Reiterates Neutral on Amedisys, Maintains $101 Price Target

<p>Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly adj earnings of $1.37 per share which beat the analyst consensus estimate of $1.09 by 25.69 percent. This is a 6.8 percent decrease over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $553.00 million which missed the analyst consensus estimate of $568.20 million by 2.68 percent. This is a 0.88 percent decrease over sales of $557.89 million the same period last year.</p>


Amedisys Q2 Adj EPS $1.37 Beats $1.09 Estimate, Sales $553.00M Miss $568.20M Estimate

Upgrades

Downgrades

Initiation

Intraday Update

AFRM

APTV

BlackSky Technology Inc. Class A Common Stock

BKSY

CARM

CSIQ

CWCO

GNTX

HBNC

HUBS

INST

MDRX

MODN

NBIX

NTST

PECO

PLUG

QFIN

QLYS

RETA

RGEN

TENB

TEVA

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023

<ul>
<li>Morgan Stanley cut the price target for <strong> ArcBest Corporation </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arcb#NASDAQ">ARCB</a>) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.</li>
<li>Truist Securities increased the price target for <strong> Owens Corning </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oc#NYSE">OC</a>) from $105 to $135. Truist Securities analyst Keith Hughes maintained a Hold rating. Owens Corning shares fell 2.2% to close at $128.67 on Wednesday.</li>
<li>Goldman Sachs increased the price target for <strong> Netflix, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) from $230 to $400. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. Netflix shares fell 1.2% to $440.56 in pre-market trading.</li>
<li>Cantor Fitzgerald cut <strong> Regeneron Pharmaceuticals, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) price target from $815 to $795. Cantor Fitzgerald analyst Alethia Young maintained a Neutral rating. Regeneron Pharmaceuticals shares fell 0.7% to $713.03 in pre-market trading.</li>
<li>JMP Securities boosted <strong> Protagonist Therapeutics, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptgx#NASDAQ">PTGX</a>) price target from $28 to $35. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. Protagonist Therapeutics shares fell 1.5% to $23.05 in pre-market trading.</li>
<li>Raymond James slashed <strong> Comerica Incorporated </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cma#NYSE">CMA</a>) price target from $57 to $53. Raymond James analyst Michael Rose maintained a Strong Buy rating. Comerica shares fell 0.5% to $43.28 in pre-market trading.</li>
<li>Rosenblatt raised <strong> CME Group Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cme#NASDAQ">CME</a>) price target from $161 to $169. Rosenblatt analyst Andrew Bond maintained a Sell rating. CME Group shares fell 0.1% to $183.84 in pre-market trading.</li>
<li>B of A Securities raised the price target for <strong> BorgWarner Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bwa#NYSE">BWA</a>) from $54 to $67. B of A Securities analyst John Murphy upgraded the stock from Neutral to Buy. BorgWarner shares fell 1.7% to close at $43.18 on Wednesday.</li>
<li>Keybanc boosted <strong> Meta Platforms, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) price target from $280 to $335. Keybanc analyst Justin Patterson maintained an Overweight rating. Meta shares gained 2.9% to close at $294.37 on Wednesday.</li>
<li>Jefferies increased <strong> Amedisys, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) price target from $98 to $101. Jefferies analyst Brian Tanquilut downgraded the stock from Buy to Hold. Amedisys shares dropped 0.5% to $90.80 in pre-market trading.</li>
<li>Citigroup raised <strong> D.R. Horton, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dhi#NYSE">DHI</a>) price target from $124 to $140. Citigroup analyst Anthony Pettinari maintained a Buy rating. D.R. Horton shares fell 0.8% to $118.30 in pre-market trading.</li>
</ul>
<p>&nbsp;</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/23/07/33131101/alphabet-palo-alto-networks-and-2-other-stocks-insiders-are-selling"><em> Alphabet, Palo Alto Networks And 2 Other Stocks Insiders Are Selling </em></a></p>


<p>Jefferies  analyst Brian Tanquilut   downgrades Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Buy to Hold and raises the price target from $98 to $101.</p>


Jefferies Downgrades Amedisys to Hold, Raises Price Target to $101

ARRY

BDTX

CBOE

COHR

CTVA

EXTR

FCNCA

GAMB

GDDY

GEHC

HAMMERHEAD ENERGY INC A by Hammerhead Energy Inc.

HHRS

LECO

MKTX

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

ODFL

PAYC

PINS

PTEN

PYCR

REXR

SAIA

SQSP

SSTI

STGW

UBER

VALE

VEEV

WDAY

YEXT

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023

<p>Over the past 3 months, 11 analysts have published their opinion on Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the last 3 months, 11 analysts have offered 12-month price targets for Amedisys. The company has an average price target of $98.82 with a high of $115.00 and a low of $84.00. </p>
<p>Below is a summary of how these 11 analysts rated Amedisys over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock</p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1687885241_0.png" alt="price target chart" /></p>
<p>This current average represents a 6.01% decrease from the previous average price target of $105.14. </p>
<p><a href="https://www.benzinga.com/quote/AMED/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Amedisys analyst ratings.</strong></a></p>
<h1>Analyst Ratings: What Are They?</h1>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings for Amedisys

Amedisys dips amid report DOJ considering lawsuit to block UnitedHealth deal

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report) and Masimo (MASI – Research Rep...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)

UnitedHealth deal for Amedisys likely to close despite report of DOJ scutiny - analyst

UnitedHealth deal for Amedisys likely to close despite report of DOJ scrutiny - analyst

DOJ case against UnitedHealth could take years to resolve, says BoA

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It&rsquo;s not a bad strategy to begin with.</p>



<p>Dividend Aristocrats are stocks on the <strong>S&amp;P 500</strong> that have <a href="https://investorplace.com/2024/04/7-stocks-to-buy-on-the-brink-of-becoming-dividend-royalty/">consistently raised their payouts</a> for 25 years or more. Studies show stocks that initiate a dividend and then raise them over time have outperformed all other stocks over time. Yet, there are limits to the strategy.</p>



<p>As <strong>Walgreens Boots Alliance</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/wba-stock-quote/"><strong>WBA</strong></a></span>) showed earlier this year, even dividend royalties can run into problems. The pharmacy chain had increased its payout for almost 50 years but slashed its dividend nearly in half because it ran into money troubles. <strong>AT&amp;T</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/t-stock-quote/"><strong>T</strong></a></span>) cut its dividend in half when it spun off its entertainment division into <strong>Warner Bros Discovery</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/wbd-stock-quote/"><strong>WBD</strong></a></span>).</p>



<p>So, just focusing on how long a stock has raised its dividend is not enough. What investors need to do is focus on dividend <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> that can afford to keep making their payouts. Growing a dividend at double-digit rates and generating enough free cash flow (<span>FCF</span>) to maintain the payout ensures a business will keep sharing its wealth with investors.</p>



<p>The following seven dividend growth stocks also have the free cash flow (<a href="https://investorplace.com/stock-quotes/fcf-stock-quote/"><strong>FCF</strong></a>) to back up the payments.</p>



<h2>LVMH Moet Hennessy Louis Vuitton (LVMUY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/lvmh_lvmuy_1600-300x169.jpg" alt="The logo for the luxury goods holding company LVMH is seen through a magnifying glass on the company's website."><div>Source: Postmodern Studio / Shutterstock.com</div></div><p>Luxury goods retailer LVMH Moet Hennessy Louis Vuitton (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/lvmuy-stock-quote/"><strong>LVMUY</strong></a></span>) is one of the first dividend growth stocks to consider for your portfolio. The owner of Fendi, Dior and Dom Perignon has a 10-year compounded annual growth rate (<span>CAGR</span>) for its dividend of 12.59% while growing FCF at a 13.9% CAGR. FCF is important for dividend investors because that&rsquo;s how companies support their payout. There are only five things a business can do with the cash it has left over after paying its bills and paying a dividend is one of them.</p>



<p>LVMH is one of the top stars in luxury retail, offering goods from apparel and watches to alcohol and textiles. While it <a href="https://investorplace.com/2024/02/money-trees-3-top-stocks-to-buy-for-5000-in-annual-dividend-income/">tends to be recession-resistant,</a> the company is not bulletproof. The rich can hold out much longer than the rest of us, but even inflation and high interest rates catch up with the uber-well-to-do, too.&nbsp;</p>



<p>That&rsquo;s the situation with LVMH, which reported slowing first-quarter sales. But that&rsquo;s not surprising considering the huge growth it enjoyed last year in its first post-pandemic-free quarter. Because comparisons get easier later on, expect LVMH stock to rebound sharply. In the meantime, collect the quarterly dividend that yields 1.7% annually.</p>



<h2>UnitedHealth Group (UNH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/unh1600-300x169.jpg" alt="The UnitedHealth (UNH) headquarters in Minnetonka, Minnesota."><div>Source: Ken Wolter / Shutterstock.com</div></div><p>Health insurer <strong>UnitedHealth Group</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/unh-stock-quote/"><strong>UNH</strong></a></span>) is the next dividend growth stock investors should have on their list. It&rsquo;s another recession-resistant issue because healthcare is something you can&rsquo;t ignore, at least not for very long. Doctor visits, prescriptions and emergency services are all vital for survival, meaning the <a href="https://investorplace.com/2024/01/3-stocks-to-turn-1000-into-10000-in-10-years/">insurer will always be in demand.</a></p>



<p>That&rsquo;s played out with UnitedHealth stock, which has grown its revenue, profits and dividend in excess of 10% annually over the past decade. The dividend had a 21% CAGR over that period, while its current FCF ratio at the end of 2023 was 10%.</p>



<p>UNH views home healthcare, in particular, as a driver of the company&rsquo;s future growth. Its Optum health services unit will be a key component for its expansion. UnitedHealth, though, has been scooping up several services businesses related to the niche, including&nbsp;LHC Group and <strong>Amedisys</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amed-stock-quote/"><strong>AMED</strong></a></span>). However, the latter deal is getting scrutinized more closely by regulators. It is not essential to UnitedHealth Group&rsquo;s outlook, even if the deal is quashed.</p>



<h2>Dick&rsquo;s Sporting Goods (DKS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/dks-stock-1600-300x169.png" alt="Exterior of Dick's Sporting Goods retail store including sign and logo."><div>Source: George Sheldon via Shutterstock</div></div><p>Outdoor action retailer <strong>Dick&rsquo;s Sporting Goods</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/dks-stock-quote/"><strong>DKS</strong></a></span>) continues building on its impressive record of dividend growth. Its average payout was 27% for the last 10 years, while it generated FCF at the white-hot rate of 33% annually.</p>



<p>Even when sales faltered, such as when it chose to get caught up in the gun control debate and eliminate firearms from its stores, Dick&rsquo;s kept growing the dividend. A boycott by hunters and other shooting sports enthusiasts sent sales reeling for a year. However, Dick&rsquo;s chose to focus on higher margin sales, such as baseball apparel and equipment, which eventually padded its bottom line. Firearms were a popular item but were a low-margin business.</p>



<p>Today, Dick&rsquo;s <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1089063/000108906324000011/dks-20240313.htm">business is robust.</a> Net sales jumped 5% last year, generating gross profit growth of 14.4%. The retailer also raised its dividend by 10% to $1.10 per share each quarter.</p>



<h2>Domino&rsquo;s (DPZ)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/dominos-pizza-stock-large-300x169.jpg" alt="Domino's (DPZ) sign on a building at night"><div>Source: Shutterstock</div></div><p>Pizza delivery specialist <strong>Domino&rsquo;s</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/dpz-stock-quote/"><strong>DPZ</strong></a></span>) has a history of raising its payout at high double-digit rates for the past decade, but recently announced it was increasing the payout by nearly 25% this year. Business has been strong for the pizza shop as it floods the market with stores in a strategy it calls &ldquo;fortressing.&rdquo;</p>



<p>By creating a <a href="https://investorplace.com/2024/03/dividend-delights-3-stocks-offering-investors-a-double-digit-raise-in-2024/">ubiquitous feeling about its presence,</a> Domino&rsquo;s keeps its stores uppermost in consumers&rsquo; minds when they want to order food away from home. It also saves on marketing costs, as one ad covers many stores. That&rsquo;s how sales rose 4% in 2023, but profits increased 15%.</p>



<p>Domino&rsquo;s has a near-20% CAGR for its dividend but also a better-than 12% increase in FCF. Like its big dividend hike last year, FCF surged over 25%, easily supporting the payout. With an FCF payout ratio under 35%, the pizzeria has plenty of room for future double-digit dividend increases. Look for Domino&rsquo;s to grow its dividend for many years to come.</p>



<h2>AbbVie (ABBV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/abbv1600-300x169.png" alt="Closeup of AbbVie (ABBV) building corporate office, an American biopharmaceutical company with its headquarters in Lake Bluff, Illinois, USA"><div>Source: Valeriya Zankovych / Shutterstock.com</div></div><p>Pharmaceutical stock <strong>AbbVie</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/abbv-stock-quote/"><strong>ABBV</strong></a></span>) was granted Dividend Aristocrat status because it was spun off from <strong>Abbott Labs</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/abt-stock-quote/"><strong>ABT</strong></a></span>) a decade ago. However, the offspring has gone on to outshine the former parent since then. Where Abbott Labs has a solid 9.6% dividend CAGR for the last decade, AbbVie has a 13.9% CAGR over the same period. Moreover, AbbVie is generating significantly more free cash flow as well. It produced $22 billion in FCF last year versus just $5 billion from Abbott Labs.</p>



<p>While Abbott&rsquo;s record is still a testament to its own business and is a worthwhile stock to own, AbbVie is <a href="https://investorplace.com/2024/03/3-dividend-aristocrats-with-the-largest-10-year-dividend-growth-rates/">growing at a blistering pace</a> and is even more attractive. It still produces mountains of cash, growing FCF at a 14% CAGR, it remains a stock to own now and for the long run. Even as sales of its blockbuster arthritis therapy Humira slowly ease up after losing patent protection, the pharma stock still has a portfolio of billion-dollar drugs that are taking its place.</p>



<h2>Automatic Data Processing (ADP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/adp-1600-300x169.png" alt="In this photo illustration the stock market information of Automatic Data Processing, Inc. displays on a smartphone with the logo of Automatic Data Processing, Inc. ADP stock."><div>Source: IgorGolovniov / Shutterstock</div></div><p>Payroll leader <strong>Automatic Data Processing</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/adp-stock-quote/"><strong>ADP</strong></a></span>) may be a surprise stock for some. It seems such a sleepy business to have a decade-long run growing its dividend and FCF at double-digit rates. Some stocks become so well-known and are so commonplace that they simply blend into the background. Yet, ADP stock continues churning out profits and cash that pay for its dividend year in and year out.</p>



<p>While revenue has grown at just a 5% CAGR for the past decade, profit growth has doubled that and free cash flow grew nearly 10% annually. That&rsquo;s allowed the payroll company to raise its dividend by over 11% a year almost in the shadows. In that vein, ADP raised the payout another 12% for this year.</p>



<p>Many investors will look at ADP&rsquo;s 2.3% yield and scoff at buying it. What they need to realize is that 10 years ago, its payout was $1.79 per share. Over the years, the dividend has grown 287%, meaning an investor&rsquo;s yield on cost would have nearly quadrupled as well.&nbsp;</p>



<h2>Home Depot (HD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/hd-stock-300x169.jpg" alt="Home Depot (HD) storefront on a sunny day"><div>Source: Jonathan Weiss / Shutterstock.com</div></div><p>Last, but investors shouldn&rsquo;t think of as least, is home improvement center <strong>Home Depot </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/hd-stock-quote/"><strong>HD</strong></a></span>). Although the retailer gets overshadowed by rival <strong>Lowe&rsquo;s</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/low-stock-quote/"><strong>LOW</strong></a></span>) 50-plus year history of increasing its own payout, Home Depot&rsquo;s recent record of raising its dividend is worth noting.</p>



<p>Home Depot has a 17% 10-year dividend growth CAGR compared to 20% at Lowe&rsquo;s. But Big Orange generated nearly twice as much FCF growth at 11.1% over that period as Big Blue did at 6.9%. Home Depot also generated $18 billion in FCF last year compared to $6.2 billion at Lowe&rsquo;s. So, it is growing bigger cash flows faster, which is an impressive feat.</p>



<p>That&rsquo;s likely because it has been the go-to location for professional contractors. Even in the face of rampant inflation that we&rsquo;ve seen over the past few years, which dampened the enthusiasm for home improvement projects, the retailer was able to continuously raise its payout. There aren&rsquo;t many businesses that could withstand the toll of high prices and high-interest rates, but Home Depot has stood tall through it all.</p>



<p><em>On the date of publication, Rich Duprey held a LONG position in WBA, T, WBD, LVMUY, ABBV and LOW stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a></em></p>
<div><p>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/dividend-growth-stars-7-stocks-with-10-year-double-digit-rate-hikes/">Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes

Amedisys Non-GAAP EPS of $1.03 beats by $0.02, revenue of $571.41M beats by $2.16M

Amedisys Inc (AMED) has provided an update. The latest Current Report on Form 8-K reveals that the company is providing its first-quarter supplemen...

Amedisys Inc Releases First-Quarter Supplemental Slides

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Amedisys</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amed-stock-quote/"><strong>AMED</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Amedisys reported earnings per share of $1.03. This was above the analyst estimate for EPS of $1.01.</li><li>The company reported revenue of $571.41 million.</li><li>This was 1.06% better than the analyst estimate for revenue of $565.44 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/amed-stock-earnings-amedisys-for-q1-of-2024/">AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report) and Gilead Sciences (GILD – Res...

Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)

AAPL

ABBV

AMZN

GILD

GOOG

LVMUY

MASI

Legal

Press Releases

Moore Kuehn Encourages TRTN, CFMS, AMED, and NEX Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTK

Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF

Amedisys Recognizes Suicide Prevention Awareness Month and Promotes the 988 Suicide & Crisis Lifeline

Amedisys Celebrates National Quality Week

Amedisys Reports Third Quarter 2023 Financial Results

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Amedisys Reports First Quarter 2024 Financial Results

CFMS

DBTX

PRTK

SURF

TRTN

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Agiliti

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amedisys Stock (NASDAQ:AMED), Short Interest Report

People Also Watch